About the Conference

The NCRI Cancer Conference is the major forum in the UK for showcasing the best British and international cancer research. The Conference offers unique opportunities for networking and sharing knowledge by bringing together the leading experts from all cancer research disciplines. The 2008 NCRI Cancer Conference will be held on 5–8 October 2008.

Conference at a Glance

Programme

Click here for
details of the 2008 Programme

Abstracts

For information regarding abstracts, click here

Registration

Registration for the 2008 Conference is now open

Trade

2008 Trade Exhibition booking form now available

FAQs

Read our Frequently Asked Questions

Accommodation

Book accommodation for the Conference

Press

Contact the 2008 Conference Press Team

Podcasts

Conference
Podcasts

Contact the Conference Secretariat

Silver Sponsor

Roche

Roche aims to improve people’s health and quality of life with innovative products and services for the early detection, prevention, diagnosis and treatment of disease. Part of one of the world’s leading healthcare groups, Roche in the UK employs nearly 2,000 people in pharmaceuticals and diagnostics.

Further Silver sponsorship opportunities available. For more information about becoming a sponsor, please contact our sponsorship co-ordinator

Bronze Sponsor

Bayer Schering Pharma

Prolonging life and improving quality of life – these are Bayer Schering Pharma’s aims to achieve breakthroughs in cancer therapy. The company’s Research and Development is currently directed at therapy for haematological malignancies and solid tumours.

Pfizer Ltd

Pfizer is a research-based global pharmaceutical company with a growing commitment to oncology. In addition to well-established and successful chemotherapy and hormonal products for the treatment of breast and colorectal cancers, our portfolio includes an exciting tyrosine kinase inhibitor licensed for the treatment of metastatic renal cell carcinoma and GIST. Pfizer boasts one of the broadest oncology pipelines in the industry, with over 20 candidates pre-clinical and clinical testing.

AstraZeneca

Continuing a tradition of research excellence that has led to the discovery of some of the world’s leading anti-cancer agents, AstraZeneca has a strong portfolio of developmental agents based on biologically targeted therapeutic strategies. These include targeting proliferation, angiogenesis, apoptosis and invasion.

iCafe Sponsor

GlaxoSmithKline

GlaxoSmithKline’s mission is to improve quality of human life by enabling people to do more, feel better, and live longer. GlaxoSmithKline is committed to the research and development of innovative oncology products in order to make a difference to the lives of patients with cancer.